To read the full story, subscribe or sign in.

Novosom In-Licenses Antisense CD40 Inhibitors from Isis Pharma

Aug. 27, 2008

Novosom AG in-licensed from Isis Pharmaceuticals Inc. the rights to antisense inhibitors that target CD40 mRNA for several indications, including Crohn's disease, rheumatoid arthritis and organ transplant rejection. (BioWorld International)

BioWorld Asia

Today's news in brief

BioWorld

BioWorld briefs for Dec. 30, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 30, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

BioWorld

Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...

Big pharma taps fast Asia innovation in search of next Keytruda

BioWorld

Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...